Stock Analysis·← Pickers

DERM

Journey Medical Corporation

Journey Medical Corporation (DERM) is currently in a range/mixed trend, trading above both the 50-day and 200-day moving averages. RSI is at 62.3, with 2/3 trend checks passing.

Price
$7.27
2026-07-16
Trend score
2/3
Range / Mixed
RSI (14)
62.3
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

DERM with MA50 and MA200

9.268.046.825.614.3907/3110/2401/2204/1707/15
DERM2025-07-312026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$6.23+16.78% vs price
MA200
$7.10+2.35% vs price
RSI (14)
62.3Neutral zone
MACD Signal
MixedMACD near signal line
Macro Support
$7.27–$7.500.0% below price · 4 touches
Support Quality
4 touches0.8× zone volume
Chart Summary
Trend summary for DERM

Journey Medical Corporation (DERM) looks more range-bound than strongly trending, but there are still a few supportive signs on the chart. The latest available price is $7.27, and 2 of 3 core trend checks are currently passing. Price is trading above the 50-day moving average by 16.8% and above the 200-day moving average by 2.4%.

Momentum and stretch context

DERM currently has an RSI reading of 62.3, which leans mildly positive without looking too stretched. In other words, momentum is supportive, but not yet extreme enough to dominate the entire chart read.

What traders may watch next

This page is designed to help you quickly understand what the DERM chart looks like before opening the full dashboard. The aim is not to tell you what to buy or sell, but to make it easier to judge whether the stock is trending cleanly, becoming stretched, or simply moving in a more awkward range.

Company profile

About Journey Medical Corporation

Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Claude Maraoui
Employees
58
Market cap
$200.1M
Beta
1.07
52-week range
$4.31 – $9.55
Dividend
No
Exchange
NASDAQ
Country
US
IPO date
12 Nov 2021
ISIN
US48115J1097
CUSIP
48115J109
Company profile data from Financial Modeling Prep. DERM listed on NASDAQ.
Share dilution

DERM shares outstanding over time

Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.

Mar 2019Mar 2026
Shares outstanding (latest)
27.3M
Since Mar 2019
-37.4%
Trend
Fewer shares outstanding (buybacks)
Historical shares-outstanding data from Financial Modeling Prep. DERM28 data points from Mar 2019 to Mar 2026.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about DERM

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.